Please login to the form below
metastatic non-small cell lung cancer (NSCLC).
This page shows the latest metastatic non-small cell lung cancer (NSCLC). news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours
In addition to the tumour-agnostic approval, the FDA has simultaneously granted traditional approval for Retevmo in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ... The multicentre, open-label, multi-group
Latest news
-
AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients
Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer. ... small cell lung cancer (NSCLC) in an ongoing phase 2 trial, the companies announced.
-
Roche launches digital PCR system to identify ultra-rare and emerging disease mutations
The company recently announced positive results from a phase 3 study evaluating a subcutaneous formulation of Tecentriq in cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung ... cancer (NSCLC) for whom prior
-
EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types
Vegzelma has been approved specifically for the treatment of metastatic breast cancer, non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or ... The EC approval is based on the ‘totality
-
AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients
the body of data for Enhertu for the treatment of HER2-positive metastatic breast cancer.”. ... Also in August, Enhertu received FDA approval to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC), whose tumours have
-
AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu has been approved by the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC). ... AZ and Daiichi Sankyo also announced promising results
More from news
Approximately 1 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
